About Gilead Sciences, Inc. 
Gilead Sciences, Inc.
Pharmaceuticals & Biotechnology
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Company Coordinates 
Company Details
333 LAKESIDE DR , FOSTER CITY CA : 94404
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 219 Schemes (42.51%)
Foreign Institutions
Held by 579 Foreign Institutions (20.4%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Daniel O'Day
Chairman of the Board, Chief Executive Officer
Mr. Kevin Lofton
Lead Independent Director
Dr. Jeffrey Bluestone
Director
Mr. Javier Rodriguez
Director
Mr. Anthony Welters
Director
Dr. Jacqueline Barton
Independent Director
Revenue and Profits:
Net Sales:
7,063 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,960 Million
Pharmaceuticals & Biotechnology
USD 143,785 Million (Large Cap)
15.00
NA
2.70%
0.94
47.06%
7.31






